Viralytics strengthens US patent portfolio
Viralytics Limited has been granted a key patent by US authorities covering the use of Echoviruses (including EVATAKTM) for the treatment of all cancers expressing the integrin a2b1 molecule.
EVATAK™ is the trade name for Viralytics’ proprietary formulation of the Echovirus Type 1 (EV1). EV1 attach to the outside of cells, using a specific receptor on the cell’s surface. EV1 uses the receptor, integrin a2b1 to bind and infect target cells. Types of cancer cells that express high levels of the integrin a2b1 molecule on their surface include ovarian, prostate and gastric cancers.
The US patent provides Viralytics protection over the exclusive use of integrin a2b1–binding Echoviruses, including EVATAKTM in the US until 2023. The granted US patent (Patent No. 7,485,292) is entitled: “Method of treating a malignancy in a subject via direct piconaviral-mediated oncolysis”.
Other news from the department research and development
